Ingevity Balance Sheet Health
Financial Health criteria checks 2/6
Ingevity has a total shareholder equity of $120.7M and total debt of $1.2B, which brings its debt-to-equity ratio to 1019.9%. Its total assets and total liabilities are $1.9B and $1.8B respectively. Ingevity's EBIT is $295.7M making its interest coverage ratio 3.6. It has cash and short-term investments of $76.9M.
Key information
1,019.88%
Debt to equity ratio
US$1.23b
Debt
| Interest coverage ratio | 3.6x |
| Cash | US$76.90m |
| Equity | US$120.70m |
| Total liabilities | US$1.76b |
| Total assets | US$1.88b |
Recent financial health updates
Does Ingevity (NYSE:NGVT) Have A Healthy Balance Sheet?
Sep 06
Ingevity (NYSE:NGVT) Has A Somewhat Strained Balance Sheet
Feb 20Is Ingevity (NYSE:NGVT) A Risky Investment?
Oct 13Ingevity (NYSE:NGVT) Use Of Debt Could Be Considered Risky
Jul 13Is Ingevity (NYSE:NGVT) A Risky Investment?
Mar 22Ingevity (NYSE:NGVT) Takes On Some Risk With Its Use Of Debt
Sep 22Recent updates
Is There Now An Opportunity In Ingevity Corporation (NYSE:NGVT)?
Sep 30Does Ingevity (NYSE:NGVT) Have A Healthy Balance Sheet?
Sep 06Ingevity: No Specialty Play, Awaiting External Drivers
Sep 05Ingevity Corporation (NYSE:NGVT) Shares Could Be 39% Below Their Intrinsic Value Estimate
Jun 27Subdued Growth No Barrier To Ingevity Corporation (NYSE:NGVT) With Shares Advancing 33%
May 28
Premium Markets Will Secure Long Term Value
Expansion into premium specialty chemicals and advanced materials is increasing margins and positioning for growth as sustainability trends and vehicle electrification accelerate.Why We're Not Concerned Yet About Ingevity Corporation's (NYSE:NGVT) 32% Share Price Plunge
Apr 05Ingevity (NYSE:NGVT) Has A Somewhat Strained Balance Sheet
Feb 20Ingevity Corporation (NYSE:NGVT) Shares Could Be 49% Below Their Intrinsic Value Estimate
Jan 16What Ingevity Corporation's (NYSE:NGVT) 32% Share Price Gain Is Not Telling You
Nov 07Is Ingevity (NYSE:NGVT) A Risky Investment?
Oct 13Ingevity Corporation's (NYSE:NGVT) Prospects Need A Boost To Lift Shares
Sep 08Ingevity: The Risk-Reward Ratio Is Still Unfavorable
Aug 27Ingevity Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 03Ingevity (NYSE:NGVT) Use Of Debt Could Be Considered Risky
Jul 13Should You Investigate Ingevity Corporation (NYSE:NGVT) At US$45.90?
Jun 14Are Investors Undervaluing Ingevity Corporation (NYSE:NGVT) By 44%?
Apr 18Is Ingevity (NYSE:NGVT) A Risky Investment?
Mar 22What Is Ingevity Corporation's (NYSE:NGVT) Share Price Doing?
Jan 23Ingevity Corporation (NYSE:NGVT) Doing What It Can To Lift Shares
Jan 04These Analysts Just Made An Incredible Downgrade To Their Ingevity Corporation (NYSE:NGVT) EPS Forecasts
Nov 10Is It Time To Consider Buying Ingevity Corporation (NYSE:NGVT)?
Oct 07Ingevity Corporation: The Risk To Reward Is Currently Favorable
Oct 06Ingevity (NYSE:NGVT) Takes On Some Risk With Its Use Of Debt
Sep 22Is There An Opportunity With Ingevity Corporation's (NYSE:NGVT) 31% Undervaluation?
Aug 11Ingevity Corporation: Headwinds Are Temporary
Jul 05Ingevity (NYSE:NGVT) Takes On Some Risk With Its Use Of Debt
Jun 21Is There Now An Opportunity In Ingevity Corporation (NYSE:NGVT)?
May 29Financial Position Analysis
Short Term Liabilities: NGVT's short term assets ($536.0M) exceed its short term liabilities ($393.1M).
Long Term Liabilities: NGVT's short term assets ($536.0M) do not cover its long term liabilities ($1.4B).
Debt to Equity History and Analysis
Debt Level: NGVT's net debt to equity ratio (956.2%) is considered high.
Reducing Debt: NGVT's debt to equity ratio has increased from 241.1% to 1019.9% over the past 5 years.
Debt Coverage: NGVT's debt is not well covered by operating cash flow (17.5%).
Interest Coverage: NGVT's interest payments on its debt are well covered by EBIT (3.6x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 19:12 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ingevity Corporation is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Paretosh Misra | Berenberg |
| John McNulty | BMO Capital Markets Equity Research |
| Mark Weintraub | Buckingham Research Group Inc. |